Not long ago, people who touted the prospects of psychedelic drugs might have been accused of hallucinating, but in the U.S. and elsewhere the space has expanded in recent years, as mental health treatments remain “stuck where cancer was 50 years ago,” said Roth analyst Elemer Piros.